{"id":7041,"date":"2018-09-21T12:56:42","date_gmt":"2018-09-21T12:56:42","guid":{"rendered":"https:\/\/mdanalytics.com\/?p=7041"},"modified":"2026-01-23T14:56:11","modified_gmt":"2026-01-23T14:56:11","slug":"biosimilar-use-in-cancer-treatment-current-attitues-perceptions","status":"publish","type":"post","link":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/","title":{"rendered":"Biosimilar Use in Cancer Treatment – Current attitudes and perceptions"},"content":{"rendered":"","protected":false},"excerpt":{"rendered":"

Biological drugs, protein-based products derived from living cells using biotechnology, have been used since the 1990\u2019s as a treatment option for cancer patients. Since 2009, biosimilar therapies (therapeutically equivalent subsequent entry biologics) have been available in different therapeutic areas in Canada, and are now on the verge of becoming available for use in oncology.<\/p>\n","protected":false},"author":8,"featured_media":7043,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[15],"tags":[],"country-icon":[45,44],"class_list":["post-7041","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-survey-data-canada","country-icon-canada","country-icon-united-states"],"acf":[],"yoast_head":"\nBiosimilar Use in Cancer Treatments | Biosimilars MD Analytics<\/title>\n<meta name=\"description\" content=\"MD Analytics asked 31 Canadian Oncologists and Hematologists for their views regarding biosimilar use in cancer treatment. Learn more here.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Biosimilar Use in Cancer Treatments | Biosimilars MD Analytics\" \/>\n<meta property=\"og:description\" content=\"MD Analytics asked 31 Canadian Oncologists and Hematologists for their views regarding biosimilar use in cancer treatment. Learn more here.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/\" \/>\n<meta property=\"og:site_name\" content=\"MD Analytics\" \/>\n<meta property=\"article:published_time\" content=\"2018-09-21T12:56:42+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-23T14:56:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mdanalytics.com\/wp-content\/uploads\/2026\/01\/Biosimilar-Use-In-Cancer-Treatment.png\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Daniel Turner, VP Client Services\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Daniel Turner, VP Client Services\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/\"},\"author\":{\"name\":\"Daniel Turner, VP Client Services\",\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/#\\\/schema\\\/person\\\/218842d011574fcb0bdfc3f3a5bb5e7f\"},\"headline\":\"Biosimilar Use in Cancer Treatment – Current attitudes and perceptions\",\"datePublished\":\"2018-09-21T12:56:42+00:00\",\"dateModified\":\"2026-01-23T14:56:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/\"},\"wordCount\":10,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mdanalytics.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Biosimilar-Use-In-Cancer-Treatment.png\",\"articleSection\":[\"Survey Results Canada\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/\",\"url\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/\",\"name\":\"Biosimilar Use in Cancer Treatments | Biosimilars MD Analytics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mdanalytics.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Biosimilar-Use-In-Cancer-Treatment.png\",\"datePublished\":\"2018-09-21T12:56:42+00:00\",\"dateModified\":\"2026-01-23T14:56:11+00:00\",\"description\":\"MD Analytics asked 31 Canadian Oncologists and Hematologists for their views regarding biosimilar use in cancer treatment. Learn more here.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mdanalytics.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Biosimilar-Use-In-Cancer-Treatment.png\",\"contentUrl\":\"https:\\\/\\\/mdanalytics.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Biosimilar-Use-In-Cancer-Treatment.png\",\"width\":900,\"height\":500,\"caption\":\"Biosimilar-Use-In-Cancer-Treatment\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/survey-data\\\/survey-data-canada\\\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Biosimilar Use in Cancer Treatment – Current attitudes and perceptions\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/\",\"name\":\"MD Analytics\",\"description\":\"Health And Pharmaceutical Market Research | MD Analytics ULC\",\"publisher\":{\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/#organization\",\"name\":\"MD Analytics Inc.\",\"url\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":null,\"contentUrl\":null,\"width\":null,\"height\":null,\"caption\":\"MD Analytics Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/#\\\/schema\\\/person\\\/218842d011574fcb0bdfc3f3a5bb5e7f\",\"name\":\"Daniel Turner, VP Client Services\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/mdanalytics.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Circle-DanT-1-150x150.png\",\"url\":\"https:\\\/\\\/mdanalytics.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Circle-DanT-1-150x150.png\",\"contentUrl\":\"https:\\\/\\\/mdanalytics.com\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/Circle-DanT-1-150x150.png\",\"caption\":\"Daniel Turner, VP Client Services\"},\"url\":\"https:\\\/\\\/mdanalytics.com\\\/en\\\/author\\\/dturner\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Biosimilar Use in Cancer Treatments | Biosimilars MD Analytics","description":"MD Analytics asked 31 Canadian Oncologists and Hematologists for their views regarding biosimilar use in cancer treatment. Learn more here.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/","og_locale":"en_US","og_type":"article","og_title":"Biosimilar Use in Cancer Treatments | Biosimilars MD Analytics","og_description":"MD Analytics asked 31 Canadian Oncologists and Hematologists for their views regarding biosimilar use in cancer treatment. Learn more here.","og_url":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/","og_site_name":"MD Analytics","article_published_time":"2018-09-21T12:56:42+00:00","article_modified_time":"2026-01-23T14:56:11+00:00","og_image":[{"width":900,"height":500,"url":"https:\/\/mdanalytics.com\/wp-content\/uploads\/2026\/01\/Biosimilar-Use-In-Cancer-Treatment.png","type":"image\/png"}],"author":"Daniel Turner, VP Client Services","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Daniel Turner, VP Client Services","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/#article","isPartOf":{"@id":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/"},"author":{"name":"Daniel Turner, VP Client Services","@id":"https:\/\/mdanalytics.com\/en\/#\/schema\/person\/218842d011574fcb0bdfc3f3a5bb5e7f"},"headline":"Biosimilar Use in Cancer Treatment – Current attitudes and perceptions","datePublished":"2018-09-21T12:56:42+00:00","dateModified":"2026-01-23T14:56:11+00:00","mainEntityOfPage":{"@id":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/"},"wordCount":10,"commentCount":0,"publisher":{"@id":"https:\/\/mdanalytics.com\/en\/#organization"},"image":{"@id":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/#primaryimage"},"thumbnailUrl":"https:\/\/mdanalytics.com\/wp-content\/uploads\/2026\/01\/Biosimilar-Use-In-Cancer-Treatment.png","articleSection":["Survey Results Canada"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/","url":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/","name":"Biosimilar Use in Cancer Treatments | Biosimilars MD Analytics","isPartOf":{"@id":"https:\/\/mdanalytics.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/#primaryimage"},"image":{"@id":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/#primaryimage"},"thumbnailUrl":"https:\/\/mdanalytics.com\/wp-content\/uploads\/2026\/01\/Biosimilar-Use-In-Cancer-Treatment.png","datePublished":"2018-09-21T12:56:42+00:00","dateModified":"2026-01-23T14:56:11+00:00","description":"MD Analytics asked 31 Canadian Oncologists and Hematologists for their views regarding biosimilar use in cancer treatment. Learn more here.","breadcrumb":{"@id":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/#primaryimage","url":"https:\/\/mdanalytics.com\/wp-content\/uploads\/2026\/01\/Biosimilar-Use-In-Cancer-Treatment.png","contentUrl":"https:\/\/mdanalytics.com\/wp-content\/uploads\/2026\/01\/Biosimilar-Use-In-Cancer-Treatment.png","width":900,"height":500,"caption":"Biosimilar-Use-In-Cancer-Treatment"},{"@type":"BreadcrumbList","@id":"https:\/\/mdanalytics.com\/en\/survey-data\/survey-data-canada\/biosimilar-use-in-cancer-treatment-current-attitues-perceptions\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/mdanalytics.com\/en\/"},{"@type":"ListItem","position":2,"name":"Biosimilar Use in Cancer Treatment – Current attitudes and perceptions"}]},{"@type":"WebSite","@id":"https:\/\/mdanalytics.com\/en\/#website","url":"https:\/\/mdanalytics.com\/en\/","name":"MD Analytics","description":"Health And Pharmaceutical Market Research | MD Analytics ULC","publisher":{"@id":"https:\/\/mdanalytics.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/mdanalytics.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/mdanalytics.com\/en\/#organization","name":"MD Analytics Inc.","url":"https:\/\/mdanalytics.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mdanalytics.com\/en\/#\/schema\/logo\/image\/","url":null,"contentUrl":null,"width":null,"height":null,"caption":"MD Analytics Inc."},"image":{"@id":"https:\/\/mdanalytics.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/mdanalytics.com\/en\/#\/schema\/person\/218842d011574fcb0bdfc3f3a5bb5e7f","name":"Daniel Turner, VP Client Services","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/mdanalytics.com\/wp-content\/uploads\/2026\/01\/Circle-DanT-1-150x150.png","url":"https:\/\/mdanalytics.com\/wp-content\/uploads\/2026\/01\/Circle-DanT-1-150x150.png","contentUrl":"https:\/\/mdanalytics.com\/wp-content\/uploads\/2026\/01\/Circle-DanT-1-150x150.png","caption":"Daniel Turner, VP Client Services"},"url":"https:\/\/mdanalytics.com\/en\/author\/dturner\/"}]}},"_links":{"self":[{"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/posts\/7041","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/comments?post=7041"}],"version-history":[{"count":1,"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/posts\/7041\/revisions"}],"predecessor-version":[{"id":7048,"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/posts\/7041\/revisions\/7048"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/media\/7043"}],"wp:attachment":[{"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/media?parent=7041"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/categories?post=7041"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/tags?post=7041"},{"taxonomy":"country-icon","embeddable":true,"href":"https:\/\/mdanalytics.com\/en\/wp-json\/wp\/v2\/country-icon?post=7041"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}